Jie Luo

Evaluation of miR-141-3p over-expression in ovarian cancer

Jiang-Hui Zeng, Su Huang, Yun-hua Lin, 2022, Electronic Journal of Biotechnology.

Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China

H. Pan, Jie-Bing Wang, Qing-qing Zhu, 2022, Medical science monitor : international medical journal of experimental and clinical research.

PROPHYLACTIC EFFECT OF NITRIC OXIDE DONORS ON RAT MODELS OF EGFR INHIBITORS-INDUCED CUTANEOUS TOXICITIES.

Zhaoyu Wu, Xinran Xie, Leying Chen, 2022, The Journal of investigative dermatology.

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

P. Zhang, G. Jiang, Chunyan Wu, 2022, BMC Medicine.

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy

J Zhang, Caicun Zhou, Yayi He, 2022, Clinical and experimental pharmacology & physiology.

DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug

Jiajun Hu, Zhaoyu Wu, Yuyun Chen, 2022, Genes & diseases.